293 related articles for article (PubMed ID: 29844572)
21. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
Boopalan T; Arumugam A; Parada J; Saltzstein E; Lakshmanaswamy R
Cancer Sci; 2015 Jan; 106(1):25-33. PubMed ID: 25412610
[TBL] [Abstract][Full Text] [Related]
22. [Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression].
Liu C; Zhou S; Ke CS; Li NP; Wu RL
Ai Zheng; 2007 Sep; 26(9):929-36. PubMed ID: 17927847
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
24. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
25. Curcumol Suppresses Breast Cancer Cell Metastasis by Inhibiting MMP-9 Via JNK1/2 and Akt-Dependent NF-κB Signaling Pathways.
Ning L; Ma H; Jiang Z; Chen L; Li L; Chen Q; Qi H
Integr Cancer Ther; 2016 Jun; 15(2):216-25. PubMed ID: 27125675
[TBL] [Abstract][Full Text] [Related]
26. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
[TBL] [Abstract][Full Text] [Related]
28. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
29. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
30. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
31. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
32. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
33. Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways.
Chen XW; Liu WT; Wang YX; Chen WJ; Li HY; Chen YH; Du XY; Peng FF; Zhou WD; Xu ZZ; Long HB
J Diabetes Complications; 2016 Jul; 30(5):760-9. PubMed ID: 27052152
[TBL] [Abstract][Full Text] [Related]
34. NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells.
Gionet N; Jansson D; Mader S; Pratt MA
J Cell Biochem; 2009 Jun; 107(3):448-59. PubMed ID: 19350539
[TBL] [Abstract][Full Text] [Related]
35. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway.
Takeda T; Tsubaki M; Genno S; Tomita K; Nishida S
Exp Cell Res; 2024 Mar; 436(2):113978. PubMed ID: 38382805
[TBL] [Abstract][Full Text] [Related]
36. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
Nakshatri H; Bhat-Nakshatri P; Martin DA; Goulet RJ; Sledge GW
Mol Cell Biol; 1997 Jul; 17(7):3629-39. PubMed ID: 9199297
[TBL] [Abstract][Full Text] [Related]
37. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.
Biswas DK; Dai SC; Cruz A; Weiser B; Graner E; Pardee AB
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10386-91. PubMed ID: 11517301
[TBL] [Abstract][Full Text] [Related]
38. MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression.
Pan D; Jiang C; Ma Z; Blonska M; You MJ; Lin X
Oncogene; 2016 Feb; 35(7):919-28. PubMed ID: 25982276
[TBL] [Abstract][Full Text] [Related]
39. Alternative splicing generates a truncated isoform of human TNFRSF11A (RANK) with an altered capacity to activate NF-κB.
Sirinian C; Papanastasiou AD; Zarkadis IK; Kalofonos HP
Gene; 2013 Aug; 525(1):124-9. PubMed ID: 23664977
[TBL] [Abstract][Full Text] [Related]
40. RANK and EGFR in invasive breast carcinoma.
Papanastasiou AD; Sirinian C; Plakoula E; Zolota V; Zarkadis IK; Kalofonos HP
Cancer Genet; 2017 Oct; 216-217():61-66. PubMed ID: 29025596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
